Multimodal Assessment of Frailty in Acute Stroke Patients
MAFASP
1 other identifier
observational
200
1 country
1
Brief Summary
The goal of this study is to investigate the influence of frailty on clinical and stroke characteristics, treatment and outcomes in patients with acute stroke. The main questions it aims to answer are:
- 1.How prevalent is frailty in patients with stroke?
- 2.Which impairments (e.g. undernutrion, impaired mobility, laboratory markers) contribute to frailty?
- 3.Is the outcome of frail patients worse than those without?
- 4.Are in-hospital complications more frequent in frail patients than those without?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2023
CompletedFirst Submitted
Initial submission to the registry
August 30, 2023
CompletedFirst Posted
Study publicly available on registry
September 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2024
CompletedSeptember 11, 2023
September 1, 2023
1.3 years
August 30, 2023
September 7, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Prevalence of frailty in stroke patients
Percentage of patients with frailty treated for stroke compared to all patients admitted for stroke
30 days
Rate of good functional outcome
Percentage of patients achieving a score of 0 to 2 on the modified Rankin scale (higher values indicating worse outcome, ranging from 0, no deficit, to 6, death) at 12 months follow-up
12 months
Secondary Outcomes (6)
Patient reported outcome measures (PROM)
12 months
Functional impairment in activities of daily living
12 months
Mortality rate
From date of admission until death or last follow-up, whichever comes first, assessed up to 12 months.
Cognitive outcome
12 months
Rate of rehospitalization
12 months
- +1 more secondary outcomes
Study Arms (1)
Stroke patients
Stroke patients admitted to the certified stroke-unit of the Department of Neurology, University Hospital Giessen, Germany.
Interventions
Different domains are assessed during hospital stay, these include: * Clinical scores: Clinical Frailty scale (CFS), Groningen Frailty index (GFI) * Brain frailty: assessing white matter hyperintensieties, atrophy and lacunar strokes in initial brain imaging * Laboratory values: laboratory Frailty index (FI-Lab), inflammatory markers * Nutrition: Controlling nutritional status score (CONUT-score), body mass index, dysphagia assessment (FOIS) * Mobility/strengths: de Morton Mobility Index (DEMMI), grip strenghts of non-paralytic arm via dynamometer, muscle mass estimated by sonographic measurement of the biceps brachii muscle and the rectus femoris muscle.
Eligibility Criteria
All patients admitted with the diagnosis of acute stroke treated at the certified stroke-unit will be included. All patients who consent for participation are further eligible for the outcome assessment.
You may qualify if:
- treated at the certified stroke-unit of the Dpt. of Neurology, University Hospital Giessen
- diagnosis of ischemic (including transient ischemic attack) or hemorrhagic stroke
You may not qualify if:
- withdrawal of care within 24 hours after admission
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Neurology, University Hospital Giessen
Giessen, Hesse, 35392, Germany
Related Publications (3)
Giede-Jeppe A, Bobinger T, Gerner ST, Sembill JA, Sprugel MI, Beuscher VD, Lucking H, Hoelter P, Kuramatsu JB, Huttner HB. Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage. Cerebrovasc Dis. 2017;44(1-2):26-34. doi: 10.1159/000468996. Epub 2017 Apr 19.
PMID: 28419988BACKGROUNDGiede-Jeppe A, Reichl J, Sprugel MI, Lucking H, Hoelter P, Eyupoglu IY, Kuramatsu JB, Huttner HB, Gerner ST. Neutrophil-to-lymphocyte ratio as an independent predictor for unfavorable functional outcome in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019 Feb 1;132(2):400-407. doi: 10.3171/2018.9.JNS181975. Print 2020 Feb 1.
PMID: 30717052BACKGROUNDGerner ST, Reichl J, Custal C, Brandner S, Eyupoglu IY, Lucking H, Holter P, Kallmunzer B, Huttner HB. Long-Term Complications and Influence on Outcome in Patients Surviving Spontaneous Subarachnoid Hemorrhage. Cerebrovasc Dis. 2020;49(3):307-315. doi: 10.1159/000508577. Epub 2020 Jul 3.
PMID: 32623428BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stefan Gerner, MD
Department of Neurology, University Hospital Giessen/Germany
- STUDY CHAIR
Thorsten Doeppner, MD
Department of Neurology, University Hospital Giessen/Germany
- STUDY CHAIR
Hagen Huttner, MD, PhD
Department of Neurology, University Hospital Giessen/Germany
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Associate professor
Study Record Dates
First Submitted
August 30, 2023
First Posted
September 11, 2023
Study Start
August 1, 2023
Primary Completion
October 31, 2024
Study Completion
October 31, 2024
Last Updated
September 11, 2023
Record last verified: 2023-09